Tagrisso 80 mg is a prescription medicine containing osimertinib, a targeted anticancer medicine used in specific treatment settings involving epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
AstraZeneca is associated with the reference Tagrisso brand. However, the company responsible for manufacturing, marketing authorization, importing or distributing a particular product presentation may depend on the country and supply arrangement. Patients should confirm the details printed on their own medicine packaging rather than assuming that every package has identical manufacturing or distribution information.
This page explains the company associated with the brand, the importance of manufacturer identification and the information patients should review when receiving a prescription medicine.
1. Which Company Is Associated With Tagrisso?
AstraZeneca is the pharmaceutical company associated with the reference Tagrisso brand. The brand contains osimertinib, an EGFR tyrosine kinase inhibitor developed for use in specified lung cancer treatment settings.
The company associated with a reference brand should be distinguished from the organization responsible for a particular package. Product labeling may identify separate organizations for manufacturing, marketing authorization, importation or distribution.
The precise details should be checked against the product packaging and applicable regulatory documentation. This is particularly important when a medicine is supplied through a country-specific distribution arrangement or obtained from an international supplier.
2. Understanding the Difference Between Brand Owner and Manufacturer
Several organizations may have different responsibilities within the supply chain of a prescription medicine.
Brand-associated company: The company linked to the marketed brand and its product information.
Manufacturer: The organization identified as responsible for manufacturing the medicine or a particular stage of its production, as applicable to the product documentation.
Marketing authorization holder: The organization responsible for the applicable authorization to market the medicine in a particular jurisdiction.
Importer: The organization responsible for bringing the product into a country under the applicable requirements.
Distributor or supplier: The organization involved in supplying the medicine to pharmacies, hospitals or other authorized recipients.
These roles are not necessarily held by the same organization. Patients should use the actual product labeling and relevant regulatory records to identify the responsible entities for their specific product.
3. What Is Tagrisso 80 mg?
Tagrisso 80 mg is an oral prescription medicine containing 80 mg of the active ingredient osimertinib per tablet, as identified by the product strength.
Osimertinib belongs to the class of medicines known as EGFR tyrosine kinase inhibitors. It inhibits susceptible mutant EGFR proteins involved in the growth and survival of certain lung cancer cells.
The medicine is used for defined clinical indications, depending on the applicable authorization. Treatment selection requires appropriate molecular testing and assessment by a qualified oncology professional.
The product strength does not establish that the medicine is suitable for every patient. The indication, prescribed regimen and monitoring plan must be determined by the treating healthcare professional.
4. Why Manufacturer Information Matters
Manufacturer and company information helps identify the product, establish its supply-chain context and investigate potential quality concerns.
Patients should review the product name, active ingredient, stated strength, batch or lot number, expiry date and company details on the package. The information should be consistent with the prescription and documentation supplied by the dispensing pharmacy.
If the company details are missing, unreadable or inconsistent, patients should ask a pharmacist to clarify the discrepancy before using the medicine.
Manufacturer information is one part of product identification. It does not, by itself, establish that an individual package is genuine or that it has been stored and transported appropriately.
5. Product Quality and Manufacturing Standards
Prescription medicines must meet applicable quality and regulatory requirements. Manufacturing and quality-control processes are intended to help ensure that medicines meet specified standards for identity, strength, quality and consistency.
The relevant requirements and documentation depend on the product and jurisdiction. Patients should not assume that a general statement about a pharmaceutical company establishes the manufacturing history or quality status of every package sold under a brand name.
Questions about a specific batch, suspected defect, damaged package or product recall should be directed to the dispensing pharmacist, the appropriate authorized company representative or the relevant medicine regulatory authority.
6. How to Review the Manufacturer Information on Packaging
When receiving Tagrisso 80 mg, patients and caregivers can review the packaging to understand the product’s identifying details.
Check the following information where it is provided:
- Brand name and active ingredient.
- Stated tablet strength.
- Manufacturer or other responsible company details.
- Batch or lot number.
- Expiry date.
- Product registration or authorization details, where applicable.
- Storage instructions and any other required labeling information.
The details should be legible and consistent with the dispensing documentation. Missing information or unexpected discrepancies should be clarified before the medicine is used.
Packaging can provide useful identifying information, but it cannot conclusively establish authenticity. A counterfeit product may imitate legitimate labels, company names or other identifying features.
7. The Role of Regulatory Authorities
Medicine regulatory authorities assess and oversee medicines according to the laws and procedures applicable to their jurisdictions. Their responsibilities may include product authorization, manufacturing oversight, safety monitoring, labeling requirements and responses to quality concerns.
A medicine’s approved indications, product presentation and regulatory status may differ between countries. The authorization of a product in one market should not automatically be interpreted as proof of identical authorization in another.
Patients and healthcare professionals should consult the applicable national regulatory information when confirmation of a product’s status is required.
8. Safety Information for Tagrisso 80 mg
Although osimertinib is a targeted anticancer medicine, it can cause adverse reactions. Commonly reported side effects include diarrhea, rash, dry skin, nail changes and inflammation of the mouth.
Important serious risks include interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
Patients should report new or worsening shortness of breath, persistent cough, significant eye pain, changes in vision, fainting or a rapid or irregular heartbeat. Severe or rapidly worsening symptoms require urgent medical assessment.
The manufacturer’s product information and the applicable prescribing document should be reviewed for complete warnings, precautions, interactions and monitoring recommendations.
9. Obtaining Tagrisso Through a Legitimate Supply Channel
Tagrisso is a prescription medicine and should be obtained through a legitimate pharmacy or supplier operating under applicable local requirements.
Patients should confirm that the medicine matches their prescription and that the supplier can explain the product’s origin and dispensing process. Be cautious if a seller cannot provide reliable product information, offers packaging with missing details or discourages questions about authenticity.
Price alone does not establish quality or legitimacy. A package that looks professional or displays a familiar company name may still require further verification if other details raise concern.
If the product’s origin is uncertain, consult a qualified pharmacist or appropriate regulatory authority before use.
10. What to Do if Manufacturer Details Appear Incorrect
If the packaging displays unexpected company information, inconsistent product details or possible signs of tampering, do not assume that the discrepancy is harmless.
Keep the package and related documentation available. Contact the dispensing pharmacy and ask for clarification. Depending on the concern, the pharmacist may advise contacting an authorized company representative or the appropriate regulatory authority.
Do not attempt to authenticate a medicine solely by comparing photographs online, scanning a code or checking a printed logo. These features are not conclusive proof of product identity or quality.
If the medicine has already been taken and the patient develops serious or unexpected symptoms, seek appropriate medical assistance.
Frequently Asked Questions About the Tagrisso Manufacturer
Who is associated with the Tagrisso brand?
AstraZeneca is associated with the reference Tagrisso brand. The responsible company details for a specific package should be confirmed from its labeling and applicable regulatory documentation.
Is the brand-associated company always the manufacturer?
Not necessarily. The brand-associated company, manufacturer, marketing authorization holder, importer and distributor may have different responsibilities.
Does the company name on a package prove authenticity?
No. Company information helps identify a product but cannot independently prove that an individual package is genuine.
Why might company details differ between countries?
Manufacturing, authorization, importation and distribution arrangements can vary according to the product presentation and national regulatory framework.
What should I do if company information is missing?
Ask the dispensing pharmacist to clarify the product identity and responsible company information before using the medicine.
Can I rely on a package photograph to verify Tagrisso?
No. A photograph may show visible details but cannot establish the contents, quality, storage history or authenticity of the actual medicine.
Conclusion
AstraZeneca is associated with the reference Tagrisso brand, whose active ingredient is osimertinib. However, the manufacturer and other responsible organizations for a specific product presentation should be identified through the actual packaging and applicable regulatory documentation.
Patients should confirm the medicine name, strength, batch or lot number, expiry date and company details, and obtain prescription medicines through legitimate supply channels. Any concern about product identity, packaging or supply history should be discussed with a qualified pharmacist or appropriate regulatory authority.
Medical Disclaimer: This page provides general educational information and does not verify the manufacturer, authenticity, quality or regulatory status of any specific package. Company roles and product authorizations may vary by jurisdiction. Always follow the instructions of your prescribing healthcare professional and consult a qualified pharmacist when product information is unclear.